Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 58 entries
View as:

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

Phase: N/A Priority: Normal
NCT ID: NCT00315874 Org: User:
Start: 04/30/97 End: 01/31/98 Due: 01/31/99

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Phase: N/A Priority: Normal
NCT ID: NCT01101321 Org: User:
Start: 06/30/08 End: 11/30/08 Due: 11/30/09

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT02847702 Org: User:
Start: 08/31/16 End: 11/22/16 Due: 11/22/17

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

Phase: N/A Priority: Normal
NCT ID: NCT00531427 Org: User:
Start: 09/30/07 End: 11/30/09 Due: 11/30/10

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT01427270 Org: User:
Start: 08/31/11 End: 10/31/14 Due: 10/31/15

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

Phase: N/A Priority: Normal
NCT ID: NCT00313833 Org: User:
Start: 12/31/00 End: 11/30/01 Due: 11/30/02

Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System

Phase: N/A Priority: Normal
NCT ID: NCT03299556 Org: User:
Start: 10/05/17 End: 11/30/19 Due: 11/30/20

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT00313014 Org: User:
Start: 02/29/04 End: 09/30/05 Due: 09/30/06

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Phase: N/A Priority: Normal
NCT ID: NCT01192295 Org: User:
Start: 11/30/10 End: 07/31/14 Due: 07/31/15

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

Phase: N/A Priority: Normal
NCT ID: NCT00312195 Org: User:
Start: 03/31/01 End: 07/31/01 Due: 07/31/02

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01101165 Org: User:
Start: 02/28/07 End: 07/31/07 Due: 07/31/08

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Phase: N/A Priority: Normal
NCT ID: NCT01259102 Org: User:
Start: 11/30/00 End: 03/31/01 Due: 03/31/02

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Phase: N/A Priority: Normal
NCT ID: NCT00312221 Org: User:
Start: 04/30/04 End: 08/31/05 Due: 08/31/06

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

Phase: N/A Priority: Normal
NCT ID: NCT00320801 Org: User:
Start: 01/31/04 End: 03/31/05 Due: 03/31/06

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

Phase: N/A Priority: Normal
NCT ID: NCT01135524 Org: User:
Start: 04/30/04 End: 08/31/05 Due: 08/31/06

Clinical Outcomes From Nalmefene

Phase: N/A Priority: Normal
NCT ID: NCT05808881 Org: User:
Start: 06/30/23 End: 05/31/24 Due: 05/31/25

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT01688934 Org: User:
Start: 09/30/12 End: 08/31/13 Due: 08/31/14

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Phase: N/A Priority: Normal
NCT ID: NCT01101308 Org: User:
Start: 07/31/08 End: 01/31/09 Due: 01/31/10

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Phase: N/A Priority: Normal
NCT ID: NCT01369615 Org: User:
Start: 10/31/11 End: 05/31/14 Due: 05/31/15

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT01160614 Org: User:
Start: 07/31/10 End: 08/31/11 Due: 08/31/12

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01099709 Org: User:
Start: 01/31/07 End: 08/31/07 Due: 08/31/08

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Phase: N/A Priority: Normal
NCT ID: NCT00313846 Org: User:
Start: 04/30/03 End: 06/30/04 Due: 06/30/05

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT00490919 Org: User:
Start: 06/30/07 End: 10/31/08 Due: 10/31/09

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT01151098 Org: User:
Start: 04/30/01 End: 02/28/02 Due: 02/28/03

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Phase: N/A Priority: Normal
NCT ID: NCT01125917 Org: User:
Start: 06/30/04 End: 01/31/08 Due: 01/31/09